Harbor Investment Advisory LLC Has $253,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Harbor Investment Advisory LLC boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,286 shares of the medical research company’s stock after acquiring an additional 58 shares during the period. Harbor Investment Advisory LLC’s holdings in IQVIA were worth $253,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Simplify Asset Management Inc. boosted its position in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Versor Investments LP bought a new position in shares of IQVIA during the third quarter worth $1,328,000. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its position in shares of IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after purchasing an additional 8,490 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.2 %

Shares of IQV stock opened at $205.37 on Thursday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm’s 50-day moving average is $199.53 and its 200-day moving average is $221.30. The stock has a market cap of $37.27 billion, a price-to-earnings ratio of 26.95, a PEG ratio of 2.01 and a beta of 1.48. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on IQV shares. Robert W. Baird reduced their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. TD Cowen cut their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.